Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 20 entries
Sorted by: Best Match Show Resources per page
Response to Dr furebring.

Bone marrow transplantation

Ringden O, Tollemar J.
PMID: 10673712
Bone Marrow Transplant. 2000 Feb;25(3):342-3. doi: 10.1038/sj.bmt.1702157.

No abstract available.

Cite
Ringden O, Tollemar J. Response to Dr furebring. Bone Marrow Transplant. 2000;25(3):342-3doi: 10.1038/sj.bmt.1702157.
Ringden, O., & Tollemar, J. (2000). Response to Dr furebring. Bone marrow transplantation, 25(3), 342-3. https://doi.org/10.1038/sj.bmt.1702157
Ringden, and Tollemar. "Response to Dr furebring." Bone marrow transplantation vol. 25,3 (2000): 342-3. doi: https://doi.org/10.1038/sj.bmt.1702157
Ringden O, Tollemar J. Response to Dr furebring. Bone Marrow Transplant. 2000 Feb;25(3):342-3. doi: 10.1038/sj.bmt.1702157. PMID: 10673712.
Copy Download .nbib Format: NLM
Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis.

Frontiers in immunology

Baygan A, Aronsson-Kurttila W, Moretti G, Tibert B, Dahllöf G, Klingspor L, Gustafsson B, Khoein B, Moll G, Hausmann C, Svahn BM, Westgren M, Remberger M, Sadeghi B, Ringden O.
PMID: 28744284
Front Immunol. 2017 Jul 11;8:795. doi: 10.3389/fimmu.2017.00795. eCollection 2017.

Mesenchymal stromal cells (MSCs) are increasingly used in regenerate medicine. Placenta-derived decidual stromal cells (DSCs) are a novel therapy for acute graft-versus-host-disease (GVHD) and hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT). DSCs are more immunosuppressive than...

Cite
Baygan A, Aronsson-Kurttila W, Moretti G, et al. Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis. Front Immunol. 2017;8:795doi: 10.3389/fimmu.2017.00795.
Baygan, A., Aronsson-Kurttila, W., Moretti, G., Tibert, B., Dahllöf, G., Klingspor, L., Gustafsson, B., Khoein, B., Moll, G., Hausmann, C., Svahn, B. M., Westgren, M., Remberger, M., Sadeghi, B., & Ringden, O. (2017). Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis. Frontiers in immunology, 8795. https://doi.org/10.3389/fimmu.2017.00795
Baygan, Arjang, et al. "Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis." Frontiers in immunology vol. 8 (2017): 795. doi: https://doi.org/10.3389/fimmu.2017.00795
Baygan A, Aronsson-Kurttila W, Moretti G, Tibert B, Dahllöf G, Klingspor L, Gustafsson B, Khoein B, Moll G, Hausmann C, Svahn BM, Westgren M, Remberger M, Sadeghi B, Ringden O. Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis. Front Immunol. 2017 Jul 11;8:795. doi: 10.3389/fimmu.2017.00795. eCollection 2017. PMID: 28744284; PMCID: PMC5504152.
Copy Download .nbib Format: NLM
Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib.

BMC hematology

Pálmason R, Lindén O, Richter J.
PMID: 26167286
BMC Hematol. 2015 Jul 11;15:10. doi: 10.1186/s12878-015-0029-1. eCollection 2015.

BACKGROUND: Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations. EBV reactivation has...

Cite
Pálmason R, Lindén O, Richter J. Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib. BMC Hematol. 2015;15:10doi: 10.1186/s12878-015-0029-1.
Pálmason, R., Lindén, O., & Richter, J. (2015). Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib. BMC hematology, 1510. https://doi.org/10.1186/s12878-015-0029-1
Pálmason, Róbert, et al. "Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib." BMC hematology vol. 15 (2015): 10. doi: https://doi.org/10.1186/s12878-015-0029-1
Pálmason R, Lindén O, Richter J. Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib. BMC Hematol. 2015 Jul 11;15:10. doi: 10.1186/s12878-015-0029-1. eCollection 2015. PMID: 26167286; PMCID: PMC4498562.
Copy Download .nbib Format: NLM
The multifactorial etiology of graft-versus-host disease.

Immunology today

de Gast GC, Gratama JW, Ringden O, Gluckman E.
PMID: 25290429
Immunol Today. 1987;8(7):209-12. doi: 10.1016/0167-5699(87)90166-6.

Graft-versus-host disease (GVHD), a major complication of bone marrow transplantation, often occurs despite genotypic HLA identity between patient and donor. Here, Gijsbert de Gast and his colleagues suggest that pretransplant cytoreductive therapy reactives latent virus and protozoan infections and...

Cite
de Gast GC, Gratama JW, Ringden O, et al. The multifactorial etiology of graft-versus-host disease. Immunol Today. 1987;8(7):209-12doi: 10.1016/0167-5699(87)90166-6.
de Gast, G. C., Gratama, J. W., Ringden, O., & Gluckman, E. (1987). The multifactorial etiology of graft-versus-host disease. Immunology today, 8(7), 209-12. https://doi.org/10.1016/0167-5699(87)90166-6
de Gast, G C, et al. "The multifactorial etiology of graft-versus-host disease." Immunology today vol. 8,7 (1987): 209-12. doi: https://doi.org/10.1016/0167-5699(87)90166-6
de Gast GC, Gratama JW, Ringden O, Gluckman E. The multifactorial etiology of graft-versus-host disease. Immunol Today. 1987;8(7):209-12. doi: 10.1016/0167-5699(87)90166-6. PMID: 25290429.
Copy Download .nbib Format: NLM
A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer.

Journal of immunotherapy (Hagerstown, Md. : 1997)

Omazic B, Ayoglu B, Löhr M, Segersvärd R, Verbeke C, Magalhaes I, Potacova Z, Mattsson J, Terman A, Ghazi S, Albiin N, Kartalis N, Nilsson P, Poiret T, Zhenjiang L, Heuchel R, Schwenk JM, Permert J, Maeurer MJ, Ringden O.
PMID: 28338506
J Immunother. 2017 May;40(4):132-139. doi: 10.1097/CJI.0000000000000164.

We examined the immunologic effects of allogeneic hematopoietic stem cell transplantation (HSCT) in the treatment of pancreatic ductal adenocarcinoma, a deadly disease with a median survival of 24 months for resected tumors and a 5-year survival rate of 6%....

Cite
Omazic B, Ayoglu B, Löhr M, et al. A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer. J Immunother. 2017;40(4):132-139doi: 10.1097/CJI.0000000000000164.
Omazic, B., Ayoglu, B., Löhr, M., Segersvärd, R., Verbeke, C., Magalhaes, I., Potacova, Z., Mattsson, J., Terman, A., Ghazi, S., Albiin, N., Kartalis, N., Nilsson, P., Poiret, T., Zhenjiang, L., Heuchel, R., Schwenk, J. M., Permert, J., Maeurer, M. J., & Ringden, O. (2017). A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer. Journal of immunotherapy (Hagerstown, Md. : 1997), 40(4), 132-139. https://doi.org/10.1097/CJI.0000000000000164
Omazic, Brigitta, et al. "A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer." Journal of immunotherapy (Hagerstown, Md. : 1997) vol. 40,4 (2017): 132-139. doi: https://doi.org/10.1097/CJI.0000000000000164
Omazic B, Ayoglu B, Löhr M, Segersvärd R, Verbeke C, Magalhaes I, Potacova Z, Mattsson J, Terman A, Ghazi S, Albiin N, Kartalis N, Nilsson P, Poiret T, Zhenjiang L, Heuchel R, Schwenk JM, Permert J, Maeurer MJ, Ringden O. A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer. J Immunother. 2017 May;40(4):132-139. doi: 10.1097/CJI.0000000000000164. PMID: 28338506.
Copy Download .nbib Format: NLM
[No title available]

Cancer biotherapy & radiopharmaceuticals

Lindén O, Bates AT, Cunningham D, Hindorf C, Larsson E, Cleton A, Pinkert J, Huang F, Bladt F, Hennekes H, Oedegaardstuen LI, Sturm I, McNamara C.
PMID: 33887152
Cancer Biother Radiopharm. 2021 Oct;36(8):672-681. doi: 10.1089/cbr.2020.4653. Epub 2021 Apr 21.

No abstract available.

Cite
Lindén O, Bates AT, Cunningham D, et al. . Cancer Biother Radiopharm. 2021;36(8):672-681doi: 10.1089/cbr.2020.4653.
Lindén, O., Bates, A. T., Cunningham, D., Hindorf, C., Larsson, E., Cleton, A., Pinkert, J., Huang, F., Bladt, F., Hennekes, H., Oedegaardstuen, L. I., Sturm, I., & McNamara, C. (2021). . Cancer biotherapy & radiopharmaceuticals, 36(8), 672-681. https://doi.org/10.1089/cbr.2020.4653
Lindén, Ola, et al. "." Cancer biotherapy & radiopharmaceuticals vol. 36,8 (2021): 672-681. doi: https://doi.org/10.1089/cbr.2020.4653
Lindén O, Bates AT, Cunningham D, Hindorf C, Larsson E, Cleton A, Pinkert J, Huang F, Bladt F, Hennekes H, Oedegaardstuen LI, Sturm I, McNamara C. . Cancer Biother Radiopharm. 2021 Oct;36(8):672-681. doi: 10.1089/cbr.2020.4653. Epub 2021 Apr 21. PMID: 33887152.
Copy Download .nbib Format: NLM
Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy.

Transplantation and cellular therapy

Orfali N, Zhang MJ, Allbee-Johnson M, Boelens JJ, Artz AS, Brunstein CG, McNiece IK, Milano F, Abid MB, Chee L, Diaz MA, Grunwald MR, Hematti P, Hsu J, Lazarus HM, Munshi PN, Prestidge T, Ringden O, Rizzieri D, Riches ML, Seo S, Solh M, Solomon S, Szwajcer D, Yared J, van Besien K, Eapen M.
PMID: 34507002
Transplant Cell Ther. 2021 Dec;27(12):993.e1-993.e8. doi: 10.1016/j.jtct.2021.08.031. Epub 2021 Oct 02.

The in vivo depletion of recipient and donor T lymphocytes using antithymocyte globulin (ATG; Thymoglobulin) is widely adopted in allogeneic hematopoietic stem cell transplantation (HCT) to reduce the incidence of both graft failure and graft-versus-host disease (GVHD). However, excess...

Cite
Orfali N, Zhang MJ, Allbee-Johnson M, et al. Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. Transplant Cell Ther. 2021;27(12):993.e1-993.e8doi: 10.1016/j.jtct.2021.08.031.
Orfali, N., Zhang, M. J., Allbee-Johnson, M., Boelens, J. J., Artz, A. S., Brunstein, C. G., McNiece, I. K., Milano, F., Abid, M. B., Chee, L., Diaz, M. A., Grunwald, M. R., Hematti, P., Hsu, J., Lazarus, H. M., Munshi, P. N., Prestidge, T., Ringden, O., Rizzieri, D., Riches, M. L., Seo, S., Solh, M., Solomon, S., Szwajcer, D., Yared, J., van Besien, K., & Eapen, M. (2021). Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. Transplantation and cellular therapy, 27(12), 993.e1-993.e8. https://doi.org/10.1016/j.jtct.2021.08.031
Orfali, Nina, et al. "Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy." Transplantation and cellular therapy vol. 27,12 (2021): 993.e1-993.e8. doi: https://doi.org/10.1016/j.jtct.2021.08.031
Orfali N, Zhang MJ, Allbee-Johnson M, Boelens JJ, Artz AS, Brunstein CG, McNiece IK, Milano F, Abid MB, Chee L, Diaz MA, Grunwald MR, Hematti P, Hsu J, Lazarus HM, Munshi PN, Prestidge T, Ringden O, Rizzieri D, Riches ML, Seo S, Solh M, Solomon S, Szwajcer D, Yared J, van Besien K, Eapen M. Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. Transplant Cell Ther. 2021 Dec;27(12):993.e1-993.e8. doi: 10.1016/j.jtct.2021.08.031. Epub 2021 Oct 02. PMID: 34507002.
Copy Download .nbib Format: NLM
Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults.

Transplantation and cellular therapy

Metheny L, Callander NS, Hall AC, Zhang MJ, Bo-Subait K, Wang HL, Agrawal V, Al-Homsi AS, Assal A, Bacher U, Beitinjaneh A, Bejanyan N, Bhatt VR, Bredeson C, Byrne M, Cairo M, Cerny J, DeFilipp Z, Perez MAD, Freytes CO, Ganguly S, Grunwald MR, Hashmi S, Hildebrandt GC, Inamoto Y, Kanakry CG, Kharfan-Dabaja MA, Lazarus HM, Lee JW, Nathan S, Nishihori T, Olsson RF, Ringdén O, Rizzieri D, Savani BN, Savoie ML, Seo S, van der Poel M, Verdonck LF, Wagner JL, Yared JA, Hourigan CS, Kebriaei P, Litzow M, Sandmaier BM, Saber W, Weisdorf D, de Lima M.
PMID: 34428556
Transplant Cell Ther. 2021 Nov;27(11):923.e1-923.e12. doi: 10.1016/j.jtct.2021.08.010. Epub 2021 Aug 21.

Patients who develop therapy-related myeloid neoplasm, either myelodysplastic syndrome (t-MDS) or acute myelogenous leukemia (t-AML), have a poor prognosis. An earlier Center for International Blood and Marrow Transplant Research (CIBMTR) analysis of 868 allogeneic hematopoietic cell transplantations (allo-HCTs) performed...

Cite
Metheny L, Callander NS, Hall AC, et al. Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. Transplant Cell Ther. 2021;27(11):923.e1-923.e12doi: 10.1016/j.jtct.2021.08.010.
Metheny, L., Callander, N. S., Hall, A. C., Zhang, M. J., Bo-Subait, K., Wang, H. L., Agrawal, V., Al-Homsi, A. S., Assal, A., Bacher, U., Beitinjaneh, A., Bejanyan, N., Bhatt, V. R., Bredeson, C., Byrne, M., Cairo, M., Cerny, J., DeFilipp, Z., Perez, M. A. D., Freytes, C. O., Ganguly, S., Grunwald, M. R., Hashmi, S., Hildebrandt, G. C., Inamoto, Y., Kanakry, C. G., Kharfan-Dabaja, M. A., Lazarus, H. M., Lee, J. W., Nathan, S., Nishihori, T., Olsson, R. F., Ringdén, O., Rizzieri, D., Savani, B. N., Savoie, M. L., Seo, S., van der Poel, M., Verdonck, L. F., Wagner, J. L., Yared, J. A., Hourigan, C. S., Kebriaei, P., Litzow, M., Sandmaier, B. M., Saber, W., Weisdorf, D., & de Lima, M. (2021). Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. Transplantation and cellular therapy, 27(11), 923.e1-923.e12. https://doi.org/10.1016/j.jtct.2021.08.010
Metheny, Leland, et al. "Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults." Transplantation and cellular therapy vol. 27,11 (2021): 923.e1-923.e12. doi: https://doi.org/10.1016/j.jtct.2021.08.010
Metheny L, Callander NS, Hall AC, Zhang MJ, Bo-Subait K, Wang HL, Agrawal V, Al-Homsi AS, Assal A, Bacher U, Beitinjaneh A, Bejanyan N, Bhatt VR, Bredeson C, Byrne M, Cairo M, Cerny J, DeFilipp Z, Perez MAD, Freytes CO, Ganguly S, Grunwald MR, Hashmi S, Hildebrandt GC, Inamoto Y, Kanakry CG, Kharfan-Dabaja MA, Lazarus HM, Lee JW, Nathan S, Nishihori T, Olsson RF, Ringdén O, Rizzieri D, Savani BN, Savoie ML, Seo S, van der Poel M, Verdonck LF, Wagner JL, Yared JA, Hourigan CS, Kebriaei P, Litzow M, Sandmaier BM, Saber W, Weisdorf D, de Lima M. Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. Transplant Cell Ther. 2021 Nov;27(11):923.e1-923.e12. doi: 10.1016/j.jtct.2021.08.010. Epub 2021 Aug 21. PMID: 34428556.
Copy Download .nbib Format: NLM
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia.

Blood advances

Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada-Merly N, Marks DI, Al-Homsi AS, Muffly L, Chao N, Rizzieri D, Gale RP, Gadalla SM, Cairo M, Mussetti A, Gore S, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan-Dabaja MA, Lazarus HM, Ganguly S, Bredeson C, Diaz Perez MA, Cassaday R, Savani BN, Ballen K, Martino R, Wirk B, Bacher U, Aljurf M, Bashey A, Murthy HS, Yared JA, Aldoss I, Farhadfar N, Liu H, Abdel-Azim H, Waller EK, Solh M, Seftel MD, van der Poel M, Grunwald MR, Liesveld JL, Kamble RT, McGuirk J, Munker R, Cahn JY, Lee JW, Freytes CO, Krem MM, Winestone LE, Gergis U, Nathan S, Olsson RF, Verdonck LF, Sharma A, Ringdén O, Friend BD, Cerny J, Choe H, Chhabra S, Nishihori T, Seo S, George B, Baxter-Lowe LA, Hildebrandt GC, de Lima M, Litzow M, Kebriaei P, Hourigan CS, Abid MB, Weisdorf DJ, Saber W.
PMID: 34547770
Blood Adv. 2022 Jan 11;6(1):339-357. doi: 10.1182/bloodadvances.2021004916.

The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission....

Cite
Wieduwilt MJ, Metheny L, Zhang MJ, et al. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Adv. 2022;6(1):339-357doi: 10.1182/bloodadvances.2021004916.
Wieduwilt, M. J., Metheny, L., Zhang, M. J., Wang, H. L., Estrada-Merly, N., Marks, D. I., Al-Homsi, A. S., Muffly, L., Chao, N., Rizzieri, D., Gale, R. P., Gadalla, S. M., Cairo, M., Mussetti, A., Gore, S., Bhatt, V. R., Patel, S. S., Michelis, F. V., Inamoto, Y., Badawy, S. M., Copelan, E., Palmisiano, N., Kharfan-Dabaja, M. A., Lazarus, H. M., Ganguly, S., Bredeson, C., Diaz Perez, M. A., Cassaday, R., Savani, B. N., Ballen, K., Martino, R., Wirk, B., Bacher, U., Aljurf, M., Bashey, A., Murthy, H. S., Yared, J. A., Aldoss, I., Farhadfar, N., Liu, H., Abdel-Azim, H., Waller, E. K., Solh, M., Seftel, M. D., van der Poel, M., Grunwald, M. R., Liesveld, J. L., Kamble, R. T., McGuirk, J., Munker, R., Cahn, J. Y., Lee, J. W., Freytes, C. O., Krem, M. M., Winestone, L. E., Gergis, U., Nathan, S., Olsson, R. F., Verdonck, L. F., Sharma, A., Ringdén, O., Friend, B. D., Cerny, J., Choe, H., Chhabra, S., Nishihori, T., Seo, S., George, B., Baxter-Lowe, L. A., Hildebrandt, G. C., de Lima, M., Litzow, M., Kebriaei, P., Hourigan, C. S., Abid, M. B., Weisdorf, D. J., & Saber, W. (2022). Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood advances, 6(1), 339-357. https://doi.org/10.1182/bloodadvances.2021004916
Wieduwilt, Matthew J, et al. "Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia." Blood advances vol. 6,1 (2022): 339-357. doi: https://doi.org/10.1182/bloodadvances.2021004916
Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada-Merly N, Marks DI, Al-Homsi AS, Muffly L, Chao N, Rizzieri D, Gale RP, Gadalla SM, Cairo M, Mussetti A, Gore S, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan-Dabaja MA, Lazarus HM, Ganguly S, Bredeson C, Diaz Perez MA, Cassaday R, Savani BN, Ballen K, Martino R, Wirk B, Bacher U, Aljurf M, Bashey A, Murthy HS, Yared JA, Aldoss I, Farhadfar N, Liu H, Abdel-Azim H, Waller EK, Solh M, Seftel MD, van der Poel M, Grunwald MR, Liesveld JL, Kamble RT, McGuirk J, Munker R, Cahn JY, Lee JW, Freytes CO, Krem MM, Winestone LE, Gergis U, Nathan S, Olsson RF, Verdonck LF, Sharma A, Ringdén O, Friend BD, Cerny J, Choe H, Chhabra S, Nishihori T, Seo S, George B, Baxter-Lowe LA, Hildebrandt GC, de Lima M, Litzow M, Kebriaei P, Hourigan CS, Abid MB, Weisdorf DJ, Saber W. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Adv. 2022 Jan 11;6(1):339-357. doi: 10.1182/bloodadvances.2021004916. PMID: 34547770; PMCID: PMC8753217.
Copy Download .nbib Format: NLM
Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia.

Blood advances

Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada-Merly N, Marks DI, Al-Homsi AS, Muffly L, Chao NJ, Rizzieri D, Gale RP, Gadalla SM, Cairo MS, Mussetti A, Gore SD, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan-Dabaja MA, Lazarus HM, Ganguly S, Bredeson CN, Diaz Perez MA, Cassaday R, Savani BN, Ballen KK, Martino R, Wirk B, Bacher U, Aljurf M, Bashey A, Murthy HS, Yared JA, Aldoss I, Farhadfar N, Liu H, Abdel-Azim H, Waller EK, Solh M, Seftel M, van der Poel MWM, Grunwald MR, Liesveld JL, Kamble RT, McGuirk JP, Munker R, Cahn JY, Lee JW, Freytes CO, Krem M, Winestone LE, Gergis U, Nathan S, Olsson RF, Verdonck LF, Sharma A, Ringden O, Friend BD, Cerny J, Choe HK, Chhabra S, Nishihori T, Seo S, George B, Baxter-Lowe LA, Hildebrandt GC, de Lima M, Litzow MR, Kebriaei P, Hourigan CS, Abid MB, Weisdorf DJ, Saber W.
PMID: 34547770
Blood Adv. 2021 Sep 21; doi: 10.1182/bloodadvances.2021004916. Epub 2021 Sep 21.

The role of haploidentical hematopoietic cell transplantation (HCT) using post-transplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariate analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission....

Cite
Wieduwilt MJ, Metheny L, Zhang MJ, et al. Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Adv. 2021;doi: 10.1182/bloodadvances.2021004916.
Wieduwilt, M. J., Metheny, L., Zhang, M. J., Wang, H. L., Estrada-Merly, N., Marks, D. I., Al-Homsi, A. S., Muffly, L., Chao, N. J., Rizzieri, D., Gale, R. P., Gadalla, S. M., Cairo, M. S., Mussetti, A., Gore, S. D., Bhatt, V. R., Patel, S. S., Michelis, F. V., Inamoto, Y., Badawy, S. M., Copelan, E., Palmisiano, N., Kharfan-Dabaja, M. A., Lazarus, H. M., Ganguly, S., Bredeson, C. N., Diaz Perez, M. A., Cassaday, R., Savani, B. N., Ballen, K. K., Martino, R., Wirk, B., Bacher, U., Aljurf, M., Bashey, A., Murthy, H. S., Yared, J. A., Aldoss, I., Farhadfar, N., Liu, H., Abdel-Azim, H., Waller, E. K., Solh, M., Seftel, M., van der Poel, M. W. M., Grunwald, M. R., Liesveld, J. L., Kamble, R. T., McGuirk, J. P., Munker, R., Cahn, J. Y., Lee, J. W., Freytes, C. O., Krem, M., Winestone, L. E., Gergis, U., Nathan, S., Olsson, R. F., Verdonck, L. F., Sharma, A., Ringden, O., Friend, B. D., Cerny, J., Choe, H. K., Chhabra, S., Nishihori, T., Seo, S., George, B., Baxter-Lowe, L. A., Hildebrandt, G. C., de Lima, M., Litzow, M. R., Kebriaei, P., Hourigan, C. S., Abid, M. B., Weisdorf, D. J., & Saber, W. (2021). Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood advances, . https://doi.org/10.1182/bloodadvances.2021004916
Wieduwilt, Matthew J, et al. "Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia." Blood advances vol. (2021). doi: https://doi.org/10.1182/bloodadvances.2021004916
Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada-Merly N, Marks DI, Al-Homsi AS, Muffly L, Chao NJ, Rizzieri D, Gale RP, Gadalla SM, Cairo MS, Mussetti A, Gore SD, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan-Dabaja MA, Lazarus HM, Ganguly S, Bredeson CN, Diaz Perez MA, Cassaday R, Savani BN, Ballen KK, Martino R, Wirk B, Bacher U, Aljurf M, Bashey A, Murthy HS, Yared JA, Aldoss I, Farhadfar N, Liu H, Abdel-Azim H, Waller EK, Solh M, Seftel M, van der Poel MWM, Grunwald MR, Liesveld JL, Kamble RT, McGuirk JP, Munker R, Cahn JY, Lee JW, Freytes CO, Krem M, Winestone LE, Gergis U, Nathan S, Olsson RF, Verdonck LF, Sharma A, Ringden O, Friend BD, Cerny J, Choe HK, Chhabra S, Nishihori T, Seo S, George B, Baxter-Lowe LA, Hildebrandt GC, de Lima M, Litzow MR, Kebriaei P, Hourigan CS, Abid MB, Weisdorf DJ, Saber W. Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Adv. 2021 Sep 21; doi: 10.1182/bloodadvances.2021004916. Epub 2021 Sep 21. PMID: 34547770.
Copy Download .nbib Format: NLM
Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.

Bone marrow transplantation

Percival ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM.
PMID: 34017072
Bone Marrow Transplant. 2021 Sep;56(9):2319. doi: 10.1038/s41409-021-01353-3.

No abstract available.

Cite
Percival ME, Wang HL, Zhang MJ, et al. Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021;56(9):2319doi: 10.1038/s41409-021-01353-3.
Percival, M. E., Wang, H. L., Zhang, M. J., Saber, W., de Lima, M., Litzow, M., Kebriaei, P., Abdel-Azim, H., Adekola, K., Aljurf, M., Bacher, U., Badawy, S. M., Beitinjaneh, A., Bejanyan, N., Bhatt, V., Byrne, M., Cahn, J. Y., Castillo, P., Chao, N., Chhabra, S., Copelan, E., Cutler, C., DeFilipp, Z., Dias, A., Diaz, M. A., Estey, E., Farhadfar, N., Frangoul, H. A., Freytes, C. O., Gale, R. P., Ganguly, S., Gowda, L., Grunwald, M., Hossain, N., Kamble, R. T., Kanakry, C. G., Kansagra, A., Kharfan-Dabaja, M. A., Krem, M., Lazarus, H. M., Lee, J. W., Liesveld, J. L., Lin, R., Liu, H., McGuirk, J., Munker, R., Murthy, H. S., Nathan, S., Nishihori, T., Olsson, R. F., Palmisiano, N., Passweg, J. R., Prestidge, T., Ringdén, O., Rizzieri, D. A., Rybka, W. B., Savoie, M. L., Schultz, K. R., Seo, S., Sharma, A., Solh, M., Strair, R., van der Poel, M., Verdonck, L. F., Yared, J. A., Weisdorf, D., & Sandmaier, B. M. (2021). Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone marrow transplantation, 56(9), 2319. https://doi.org/10.1038/s41409-021-01353-3
Percival, Mary-Elizabeth, et al. "Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation." Bone marrow transplantation vol. 56,9 (2021): 2319. doi: https://doi.org/10.1038/s41409-021-01353-3
Percival ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM. Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 Sep;56(9):2319. doi: 10.1038/s41409-021-01353-3. PMID: 34017072; PMCID: PMC8450771.
Copy Download .nbib Format: NLM
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia.

Blood advances

Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada-Merly N, Marks DI, Al-Homsi AS, Muffly L, Chao N, Rizzieri D, Gale RP, Gadalla SM, Cairo M, Mussetti A, Gore S, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan-Dabaja MA, Lazarus HM, Ganguly S, Bredeson C, Diaz Perez MA, Cassaday R, Savani BN, Ballen K, Martino R, Wirk B, Bacher U, Aljurf M, Bashey A, Murthy HS, Yared JA, Aldoss I, Farhadfar N, Liu H, Abdel-Azim H, Waller EK, Solh M, Seftel MD, van der Poel M, Grunwald MR, Liesveld JL, Kamble RT, McGuirk J, Munker R, Cahn JY, Lee JW, Freytes CO, Krem MM, Winestone LE, Gergis U, Nathan S, Olsson RF, Verdonck LF, Sharma A, Ringdén O, Friend BD, Cerny J, Choe H, Chhabra S, Nishihori T, Seo S, George B, Baxter-Lowe LA, Hildebrandt GC, de Lima M, Litzow M, Kebriaei P, Hourigan CS, Abid MB, Weisdorf DJ, Saber W.
PMID: 34547770
Blood Adv. 2022 Jan 11;6(1):339-357. doi: 10.1182/bloodadvances.2021004916.

The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission....

Cite
Wieduwilt MJ, Metheny L, Zhang MJ, et al. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Adv. 2022;6(1):339-357doi: 10.1182/bloodadvances.2021004916.
Wieduwilt, M. J., Metheny, L., Zhang, M. J., Wang, H. L., Estrada-Merly, N., Marks, D. I., Al-Homsi, A. S., Muffly, L., Chao, N., Rizzieri, D., Gale, R. P., Gadalla, S. M., Cairo, M., Mussetti, A., Gore, S., Bhatt, V. R., Patel, S. S., Michelis, F. V., Inamoto, Y., Badawy, S. M., Copelan, E., Palmisiano, N., Kharfan-Dabaja, M. A., Lazarus, H. M., Ganguly, S., Bredeson, C., Diaz Perez, M. A., Cassaday, R., Savani, B. N., Ballen, K., Martino, R., Wirk, B., Bacher, U., Aljurf, M., Bashey, A., Murthy, H. S., Yared, J. A., Aldoss, I., Farhadfar, N., Liu, H., Abdel-Azim, H., Waller, E. K., Solh, M., Seftel, M. D., van der Poel, M., Grunwald, M. R., Liesveld, J. L., Kamble, R. T., McGuirk, J., Munker, R., Cahn, J. Y., Lee, J. W., Freytes, C. O., Krem, M. M., Winestone, L. E., Gergis, U., Nathan, S., Olsson, R. F., Verdonck, L. F., Sharma, A., Ringdén, O., Friend, B. D., Cerny, J., Choe, H., Chhabra, S., Nishihori, T., Seo, S., George, B., Baxter-Lowe, L. A., Hildebrandt, G. C., de Lima, M., Litzow, M., Kebriaei, P., Hourigan, C. S., Abid, M. B., Weisdorf, D. J., & Saber, W. (2022). Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood advances, 6(1), 339-357. https://doi.org/10.1182/bloodadvances.2021004916
Wieduwilt, Matthew J, et al. "Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia." Blood advances vol. 6,1 (2022): 339-357. doi: https://doi.org/10.1182/bloodadvances.2021004916
Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada-Merly N, Marks DI, Al-Homsi AS, Muffly L, Chao N, Rizzieri D, Gale RP, Gadalla SM, Cairo M, Mussetti A, Gore S, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan-Dabaja MA, Lazarus HM, Ganguly S, Bredeson C, Diaz Perez MA, Cassaday R, Savani BN, Ballen K, Martino R, Wirk B, Bacher U, Aljurf M, Bashey A, Murthy HS, Yared JA, Aldoss I, Farhadfar N, Liu H, Abdel-Azim H, Waller EK, Solh M, Seftel MD, van der Poel M, Grunwald MR, Liesveld JL, Kamble RT, McGuirk J, Munker R, Cahn JY, Lee JW, Freytes CO, Krem MM, Winestone LE, Gergis U, Nathan S, Olsson RF, Verdonck LF, Sharma A, Ringdén O, Friend BD, Cerny J, Choe H, Chhabra S, Nishihori T, Seo S, George B, Baxter-Lowe LA, Hildebrandt GC, de Lima M, Litzow M, Kebriaei P, Hourigan CS, Abid MB, Weisdorf DJ, Saber W. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Adv. 2022 Jan 11;6(1):339-357. doi: 10.1182/bloodadvances.2021004916. PMID: 34547770.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 20 entries